CD274 and neoplasm: New nanoformulations such as CRISPR/Cas9 loaded lipid-polymer hybrid nanoparticles can also break the expression of PD-L1 in tumor cells by targeted reprogramming of the genome and provide more significant blocking of checkpoints over time.